2013
Preclinical evidence for the antihyperalgesic activity of CDP-choline in oxaliplatin-induced neuropathic pain.
Kanat O, Bagdas D, Ozboluk H, Gurun M. Preclinical evidence for the antihyperalgesic activity of CDP-choline in oxaliplatin-induced neuropathic pain. JBUON 2013, 18: 1012-8. PMID: 24344031.Peer-Reviewed Original ResearchMeSH KeywordsAnalgesicsAnimalsCytidine Diphosphate CholineDisease Models, AnimalDose-Response Relationship, DrugGABA-B Receptor AntagonistsHyperalgesiaInjections, IntraventricularMaleNeuralgiaNeurotransmitter Uptake InhibitorsNicotinic AntagonistsOrganoplatinum CompoundsOxaliplatinPain ThresholdRatsRats, Sprague-DawleyTime FactorsConceptsAntihyperalgesic effectNeuropathic painCDP-cholineNonselective muscarinic receptor antagonist atropineNonselective opioid receptor antagonist naloxoneRat paw pressure testReceptor antagonist CGP 35348Muscarinic receptor antagonist atropineNicotinic receptor antagonist mecamylamineOpioid receptor antagonist naloxoneOxaliplatin-induced neuropathic painCholine uptake inhibitor hemicholinium-3Induction of neuropathyAntagonist CGP 35348Paw pressure testGamma-amino butyric acidNicotinic acetylcholine receptorsCGP 35348Neuropatic painMechanical hyperalgesiaAntagonist atropineTime-dependent mannerPreclinical evidenceAntagonist naloxoneAntihyperalgesic activity
2012
Antihyperalgesic activity of chlorogenic acid in experimental neuropathic pain
Bagdas D, Cinkilic N, Ozboluk H, Ozyigit M, Gurun M. Antihyperalgesic activity of chlorogenic acid in experimental neuropathic pain. Journal Of Natural Medicines 2012, 67: 698-704. PMID: 23203628, DOI: 10.1007/s11418-012-0726-z.Peer-Reviewed Original ResearchConceptsChronic constrictive nerve injuryNeuropathic painAntihyperalgesic activityPeripheral neuropathic pain modelExperimental neuropathic painNeuropathic pain modelRota-rod testNovel potential therapeutic optionPotential therapeutic optionStrong therapeutic effectLatency of ratsChlorogenic acidAntihyperalgesic effectMechanical hyperalgesiaNerve injuryPain modelChronic administrationInflammatory cascadeTherapeutic optionsHistopathological changesInflammatory processTherapeutic effectAnalgesic activityPainNervous system
2011
The antihyperalgesic effect of cytidine-5′-diphosphate-choline in neuropathic and inflammatory pain models
Bagdas D, Sonat F, Hamurtekin E, Sonal S, Gurun M. The antihyperalgesic effect of cytidine-5′-diphosphate-choline in neuropathic and inflammatory pain models. Behavioural Pharmacology 2011, 22: 589-598. PMID: 21836465, DOI: 10.1097/fbp.0b013e32834a1efb.Peer-Reviewed Original ResearchConceptsNeuropathic pain modelAntihyperalgesic effectPain modelChronic constriction injury-induced neuropathic pain modelNonselective muscarinic receptor antagonist atropineNonselective opioid receptor antagonist naloxoneΓ-aminobutyric acid B receptorsNicotinic ACh receptor antagonistsReceptor antagonist CGP 35348Muscarinic receptor antagonist atropineNicotinic receptor antagonist mecamylamineOpioid receptor antagonist naloxoneCholine uptake inhibitor hemicholinium-3CDP-cholineEffect of intracerebroventricularlyAntagonist CGP 35348Central opioid receptorsInflammatory pain modelACh receptor antagonistNicotinic ACh receptorsCGP 35348Mechanical hyperalgesiaNeuropathic painAntagonist atropineAntagonist naloxone